Staphylococcus aureus?

Staphylococcus aureus is a spherical Gram-positive bacterium approximately 0.5 to 1.0 micrometers in diameter, often arranged in grape-like clusters. It colonizes the skin and nasal passages of roughly 30 to 50 per cent of the human population without causing disease, but readily causes infection when barrier defences are breached through wounds, surgical incisions, or insertion of medical devices. In the absence of reliable azo drug efficacy against resistant strains, and without the systemic treatment classes that emerged after 1928 in other worlds, S. aureus has remained the most frequent cause of hospital-acquired infection and a principal driver of serum therapy development throughout the Long Sepsis.

The bacterium was first identified by Alphonse Laveran and Jules Babès in 1885, named for the golden pigment produced by many strains in culture. Its pathogenic capacity was documented extensively in the 1890s through work on wound infection and septic arthritis. By the early twentieth century, S. aureus was recognized as the causative agent of septicaemia, childbed fever, and the catastrophic wound infections that became the signature failure of field medicine in the 1943 Sicily campaign.

The historical moment that would define the Long Sepsis occurred in September 1928, when Alexander Fleming at St. Mary's Hospital in London cultured Staphylococcus aureus colonies on a culture plate that became contaminated with a mold later identified as Penicillium notatum. The mold produced a clear halo in the bacterial lawn, a zone of inhibition later recognized as evidence of potent antibacterial activity. Fleming did not observe this contamination, or if noted, did not pursue it. The plate was washed and discarded. Had the observation been made and investigated — as Ernest Duchesne had documented similar antagonism decades earlier — the trajectory of bacterial treatment would have diverged. Instead, the plates were lost, the observation was not repeated, and S. aureus would remain for nearly a century the defining untreated infection of civilian and military medicine.

The bacterium's prevalence in hospitals became acute during World War II. Invasion casualties with penetrating wounds and compound fractures developed S. aureus sepsis at rates that overwhelmed the limited efficacy of azo drugs, forcing surgeons to amputate limbs and abandon operations to prevent toxaemic death. The 1943 Sicily landings saw gangrene mortality several times the rates recorded in previous wars, a catastrophe directly attributable to the absence of systemic antibacterial treatment. Military medical records from the North African and Mediterranean campaigns quantified the loss: of 12,400 soldiers with major wound infections documented in Sicily and southern Italy between July and September 1943, the Geneva Sanitary Bureau later estimated that 40 to 50 per cent developed fulminant S. aureus bacteraemia unresponsive to azo drug therapy.

Following the war, S. aureus shaped the institutional architecture of medicine. The Bacillary Congress of Geneva of 1952 cited S. aureus sepsis as the primary justification for asepsis maximalism, the doctrine that prevented infection through total exclusion rather than chemotherapy. Clean wards were designed around the assumption that S. aureus and other Gram-positive cocci would inevitably colonize patients, and that prevention of inoculation into sterile tissues was the only reliable approach. Surgical protocols were rewritten to minimize the time that incisions remained open. Disposable textiles, sterilized through heat and ethylene oxide, became mandatory because skin flora and environmental S. aureus were understood as inevitable contaminants.

The bacterium also drove serum therapy development. Because azo drugs showed declining efficacy against nosocomial strains of S. aureus — particularly those acquiring genetic traits for toxin production — Dorothy Umezaki and her collaborators at the Infectious Disease Research Centre focused serum therapy research on neutralizing the alpha-toxin produced by the most virulent strains. The Halloway-Umezaki method, formalized in 1979, derived much of its clinical validity from trials in S. aureus septicaemia and endocarditis, infections for which azo drugs had become nearly useless. By the early twenty-first century, serum therapy had become the treatment of last resort for acute S. aureus bacteraemia, with clinical outcomes measured through Kaplan-Meier survival analysis rather than the outright cure possible with other microbial infections in other medical traditions.

Strains of S. aureus resistant to azo drugs emerged by the 1960s, initially in hospitals and later in the community. The Geneva Sanitary Bureau began tracking resistance patterns in 1963 through the International Serum Registry, which coordinates treatment allocation and outcome reporting across nations. By 2000, methicillin-resistant strains of S. aureus had become endemic in most developed-world hospitals, and the bacterium had acquired the status of a defining pathogenic challenge in a civilization built around its prevention rather than its defeat.

The absence of definitive chemical treatment has shaped clinical practice around early diagnosis and aggressive containment. Infection with S. aureus remains a leading cause of preventable mortality in childbirth, a major hazard of surgery, and the most frequent bacterium isolated from clean wards infections despite protocols designed to exclude it. That it remains so — that prevention fails and the bacterium persists — is the condition that has structured the Long Sepsis from 1928 onward.